Roivant Sciences Ltd (ROIV)
11.22
-0.18
(-1.62%)
USD |
NASDAQ |
May 17, 16:00
11.22
0.00 (0.00%)
After-Hours: 20:00
Roivant Sciences Shareholders Equity (Quarterly): 6.090B for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.090B |
| September 30, 2023 | 948.53M |
| June 30, 2023 | 910.73M |
| March 31, 2023 | 1.158B |
| December 31, 2022 | 955.52M |
| September 30, 2022 | 1.161B |
| Date | Value |
|---|---|
| June 30, 2022 | 1.384B |
| March 31, 2022 | 1.657B |
| December 31, 2021 | 1.866B |
| September 30, 2021 | 2.038B |
| June 30, 2021 | 1.723B |
| March 31, 2021 | 1.798B |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
910.73M
Minimum
Jun 2023
6.090B
Maximum
Dec 2023
1.807B
Average
1.521B
Median
Shareholders Equity (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 24.38M |
| Biodexa Pharmaceuticals Plc | 5.959M |
| Verona Pharma PLC | 224.99M |
| NuCana PLC | 18.96M |
| Autolus Therapeutics PLC | 111.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 7.313B |
| Total Liabilities (Quarterly) | 728.10M |
| Debt to Equity Ratio | 0.0737 |
| Current Ratio | 27.79 |
| Net Debt Paydown Yield | -0.08% |